Glaxo Relents, Grants Mylan Paxil License

Law360, New York (October 23, 2007, 12:00 AM EDT) -- Mylan Inc. has settled GlaxoSmithKline Plc's infringement suit over Glaxo's blockbuster antidepressant Paxil CR, gaining the right to produce and market all three strengths of its generic version of the drug, Mylan announced Tuesday.

The settlement will see the generics maker and its subsidiary, Mylan Pharmaceuticals Inc., receive a patent license by Oct. 1, 2008. It will also see the definitive end to all litigation against Mylan relating to the Paxil CR patent.

Mylan requested Monday that a judge in the U.S. District Court for the...
To view the full article, register now.